4D Molecular Therapeutics, Inc. NMS · FDMT
Price alert —
Sign in to get a one-time email the moment FDMT crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · FDMT
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.0B | $-0.1B | $-0.1B | $-0.1B | -2256.6% | -2416.1% |
| 2025-12-31 | $0.1B | $0.0B | $0.0B | $0.0B | 22.8% | 17.3% |
| 2025-09-30 | $0.0B | $-0.1B | $-0.1B | $-0.0B | -63195.6% | -67983.3% |
| 2025-06-30 | $0.0B | $-0.1B | $-0.1B | $-0.0B | -364386.7% | -396373.3% |
| 2025-03-31 | $0.0B | $-0.0B | $-0.1B | $-0.0B | -342657.1% | -383007.1% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare FDMT vs peers
Line FDMT up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with FDMT
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-07 | -1.01 | -1.00 | -1.4% | +2.1% |
| 2026-03-18 | 0.43 | -0.53 | +181.4% | +4.9% |
| 2025-11-10 | -1.01 | -0.98 | -2.8% | +6.2% |
| 2025-08-11 | -0.98 | -0.69 | -41.4% | +11.2% |
| 2025-05-08 | -0.86 | -0.86 | +0.2% | -4.9% |
| 2025-02-28 | -0.90 | -0.84 | -7.4% | -8.6% |
| 2024-11-13 | -0.79 | -0.70 | -12.2% | +4.0% |
| 2024-08-08 | -0.63 | -0.71 | +11.0% | +0.5% |
| 2024-05-09 | -0.66 | -0.76 | +12.8% | +0.2% |
| 2024-02-29 | -0.77 | -0.73 | -5.8% | +4.8% |
| 2023-11-09 | -0.24 | -0.60 | +60.2% | +5.2% |
| 2023-08-09 | -0.77 | -0.77 | +0.4% | -2.3% |
| 2023-05-10 | -0.88 | -0.90 | +2.2% | -4.2% |
| 2023-03-15 | -0.84 | -0.73 | -15.1% | +5.7% |
| 2022-11-08 | -0.79 | -0.91 | +13.4% | +6.4% |
| 2022-08-11 | -0.87 | -0.85 | -2.4% | -8.3% |
| 2022-05-12 | -0.82 | -0.77 | -6.5% | -4.3% |
| 2022-03-28 | -0.85 | -0.86 | +1.2% | +6.1% |
| 2021-11-10 | -0.82 | -0.80 | -1.9% | +0.2% |
| 2021-08-12 | -0.28 | -0.68 | +58.8% | -3.2% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| FDMT ★ | $1B | — | -3.0 | 6.5 | -1.2 | 1.3 | -145.7% | 21664.3% | — | -12.07% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 64.44%
| Holder | Shares | % out |
|---|---|---|
| Janus Henderson Group PLC | 5,247,151 | 10.04% |
| RA Capital Management, L.P. | 5,049,779 | 9.66% |
| Goldman Sachs Group Inc | 4,205,438 | 8.04% |
| Blackrock Inc. | 4,145,303 | 7.93% |
| Novo Holdings A/S | 3,650,737 | 6.98% |
| BVF Inc. | 2,879,289 | 5.51% |
| State Street Corporation | 2,707,875 | 5.18% |
| Vanguard Capital Management LLC | 2,195,578 | 4.20% |
| Armistice Capital, LLC | 2,000,000 | 3.83% |
| Adage Capital Partners GP L.L.C. | 1,605,156 | 3.07% |
Insider activity · 90d
3 buys / 6 sells · ratio 0.5 · Finnhub
- Kirn David SELL 884,152 @ $12.84
- Kirn David SELL 884,594 @ $12.01
- Kirn David SELL 899,877 @ $12.87
- Bizily Scott M 3,543
- Bizily Scott M 62,971
- Bizily Scott SELL 8,617 @ $14.00
- Bizily Scott M 15,183 @ $6.49
- Bizily Scott M 9,431 @ $4.14
- Bizily Scott M 63,785
- Bizily Scott SELL 8,617 @ $12.00
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-07-14 | 4 | view · |
| 4 | 2026-07-02 | 4 | view · |
| 8-K | 2026-06-29 | 8-K | view · |
| 4 | 2026-06-25 | 4 | view · |
| 4 | 2026-06-23 | 4 | view · |
| 8-K | 2026-06-22 | 8-K | view · |
| 4 | 2026-06-18 | 4 | view · |
| 4 | 2026-06-18 | 4 | view · |
| 4 | 2026-06-18 | 4 | view · |
| 4 | 2026-06-18 | 4 | view · |
| 4 | 2026-06-18 | 4 | view · |
| 4 | 2026-06-18 | 4 | view · |
| 4 | 2026-06-18 | 4 | view · |
| 4 | 2026-06-02 | 4 | view · |
| 10-Q | 2026-05-07 | 10-Q | view · |
| 8-K | 2026-05-07 | 8-K | view · |
| DEF 14A | 2026-04-28 | DEF 14A | view · |
| 8-K | 2026-03-30 | 8-K | view · |
| 4 | 2026-03-27 | 4 | view · |
| 4 | 2026-03-27 | 4 | view · |
| 4 | 2026-03-27 | 4 | view · |
| 4 | 2026-03-24 | 4 | view · |
| 10-K | 2026-03-18 | 10-K | view · |
| 8-K | 2026-03-18 | 8-K | view · |
| 8-K | 2026-01-26 | 8-K | view · |
| 4 | 2026-01-07 | 4 | view · |
| 8-K | 2026-01-07 | 8-K | view · |
| 4 | 2025-12-23 | 4 | view · |
| 4 | 2025-12-19 | 4 | view · |
| 4 | 2025-12-16 | 4 | view · |
| 4 | 2025-12-11 | 4 | view · |
| 8-K | 2025-12-10 | 8-K | view · |
| 4 | 2025-11-19 | 4 | view · |
| 8-K | 2025-11-17 | 8-K | view · |
| 10-Q | 2025-11-10 | 10-Q | view · |
| 8-K | 2025-11-10 | 8-K | view · |
| 8-K | 2025-11-07 | 8-K | view · |
| 8-K | 2025-11-06 | 8-K | view · |
| 8-K | 2025-10-31 | 8-K | view · |
| 4 | 2025-10-27 | 4 | view · |
| 4 | 2025-10-20 | 4 | view · |
| 4 | 2025-10-14 | 4 | view · |
| 8-K | 2025-10-02 | 8-K | view · |
| 4 | 2025-09-26 | 4 | view · |
| 10-Q | 2025-08-11 | 10-Q | view · |
| 8-K | 2025-08-11 | 8-K | view · |
| 8-K | 2025-07-02 | 8-K | view · |
| 4 | 2025-06-20 | 4 | view · |
| 4 | 2025-06-20 | 4 | view · |
| 4 | 2025-06-20 | 4 | view · |
| 4 | 2025-06-20 | 4 | view · |
| 4 | 2025-06-20 | 4 | view · |
| 4 | 2025-06-20 | 4 | view · |
| 8-K | 2025-06-20 | 8-K | view · |
| 10-Q | 2025-05-08 | 10-Q | view · |
| 8-K | 2025-05-08 | 8-K | view · |
| DEF 14A | 2025-04-29 | DEF 14A | view · |
| 4 | 2025-03-10 | 4 | view · |
| 4 | 2025-03-10 | 4 | view · |
| 4 | 2025-03-10 | 4 | view · |
About FDMT
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Options picks · FDMT
ITM + OTM ideas from the latest scanLoading…
Congress trades · FDMT
STOCK Act disclosuresLoading…
SEC filings & insiders · FDMT
EDGAR · liveLoading…
Holders · FDMT
Institutions & insider activityLoading…